L'intérêt à découvert pour Sonim Technologies donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Sonim Technologies. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Sonim Technologies (NASDAQ:SONM) Stock, Rapport sur les intérêts à découvert

Sonim Technologies

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Sonim Technologies Inc

SONM (BEP-20)

Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock is trading lower after the company announced on Tuesday that it had revised the ongoing Registrational Expansion Cohort in the Phase 1/2 ACHIEVE trial for DYNE-101 for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">myotonic dystrophy type 1 (DM1)</a>.
The primary endpoint is a change from baseline in middle finger myotonia as measured by vHOT at 6 months, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45968516/dyne-therapeutics-announces-fda-breakthrough-therapy-designation-for-dyne-101-and-updated-plan-for" rel="noreferrer noopener">compared to placebo</a>.
<ul class="wp-block-list">
<li>Video hand opening time (vHOT) measures hand function and myotonia (delayed relaxation of skeletal muscles after voluntary contraction).</li>
</ul>
Secondary endpoints include change from baseline in splicing as measured by the composite alternative splicing index (CASI-22), muscle strength as assessed by Quantitative Muscle Testing (QMT), performance on both the 10-Meter Walk/Run Test (10MWR) and 5 Times Sit to Stand Test (5xSTS), and the Myotonic Dystrophy Health Index (MDHI) patient-reported outcome measure, all at 6 months compared to placebo.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44441276/jpmorgan-seeks-clarity-on-dyne-therapeutics-dyne-101-expansion-regulatory-path" target="_blank" rel="noreferrer noopener">JPMorgan Seeks Clarity On Dyne Therapeutics&#8217; DYNE-101 Expansion, Regulatory Path</a>
The cohort is expected to enroll 60 participants, randomized 3:1 to receive DYNE-101 6.8 mg/kg Q8W or placebo. Dyne plans to complete enrollment in the Registrational Expansion Cohort in the fourth quarter of 2025.
Dyne intends to use data from the Registrational Expansion Cohort and the already enrolled patients in the multiple ascending dose (MAD) and ongoing long-term extension portions of the ACHIEVE trial to support a potential submission for Accelerated Approval in the U.S.
Data from the cohort are planned for mid-2026 to support a potential U.S. Accelerated Approval submission in late 2026.
It seems that the company&#8217;s stock plunged as earlier Dyne expected to submit an Accelerated Approval Biologics License Application (BLA) in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45281892/dyne-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-highlights" rel="noreferrer noopener">the first half of 2026</a>.
Dyne plans to initiate a confirmatory Phase 3 clinical trial in Q1 2026.
Dyne also reported new long-term data from adult DM1 patients enrolled in the randomized, placebo-controlled MAD portion of the DYNE-101 ACHIEVE trial, including data from the 6.8 mg/kg Q8W cohort (n=6) at up to 12 months.
At the registrational dose of 6.8 mg/kg Q8W, DYNE-101 demonstrated robust and sustained improvement in myotonia as measured by vHOT and sustained improvements across multiple other endpoints.
<ul class="wp-block-list">
<li>As previously disclosed, treatment with DYNE-101 led to an improvement in vHOT of 3.3 seconds compared to placebo at 6 months.</li>
<li>New data demonstrated that mean improvements at 6 months were sustained at 12 months for vHOT, 10MWR, 5xSTS, MDHI, and QMT, which demonstrated a 10% improvement in strength at 6 months, increasing to 20% at 12 months relative to baseline.</li>
</ul>
The company expects that its $677.5 million cash, cash equivalents, and marketable securities as of March 31, 2025, will be sufficient to fund its operations into the fourth quarter of 2026.
The U.S. Food and Drug Administration (FDA) on Tuesday granted Breakthrough Therapy Designation to DYNE-101 for DM1.
Price Action: DYN stock is trading lower by 18.2% to $11.30 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45844751/avidity-biosciences-touts-encouraging-functional-gains-and-biomarker-reductions-in-rare-muscular-weakness-disease-trial" target="_blank" rel="noreferrer noopener">Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial</a></li>
</ul>
Image via Shutterstock

Biotech

News

Health Care

Movers

General

Why Is Dyne Therapeutics Stock Trading Lower On Tuesday?

RBC Capital analyst Lisa Walter initiates coverage on EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) with a Outperform rating and announces Price Target of $28.

Price Target

Initiation

Analyst Ratings

EYPT

RBC Capital Initiates Coverage On EyePoint Pharmaceuticals with Outperform Rating, Announces Price Target of $28

Trading Ideas

CERO

CERo Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 285.1%

The U.S. dollar has quietly lost nearly 10% of its value in 2025 &#8211; and in its shadow, <a href="https://www.benzinga.com/topic/gold">gold stocks have</a> turned into market standouts. 
Three of them in particular — Agnico Eagle Mines Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) and Wheaton Precious Metals Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) — have soared over 50% year-to-date, far outpacing the broader market.
<h3 class="wp-block-heading">Gold's FX Tailwind Is Real And Underrated</h3>
Gold, typically priced in dollars, becomes more attractive to foreign buyers <a href="https://www.benzinga.com/markets/economic-data/25/06/45974992/everyone-now-hates-the-dollar-is-that-the-ultimate-buy-signal">when the greenback weakens</a>.
Agnico Eagle is up 51.25%, Newmont has jumped 51.47%, and Wheaton has rallied a staggering 58.24% year-to-date.
Read Also: <a href="https://www.benzinga.com/markets/guidance/25/06/45928561/gold-biggest-boom-in-decades-and-investors-are-still-missing-out">Gold&#8217;s Biggest Boom In Decades—And Investors Are Still Missing Out</a>
Wheaton's low-cost streaming model makes it particularly sensitive to commodity price upside without the drag of high mining costs. 
Meanwhile, Agnico and Newmont are benefiting from scale and strong reserve positions in politically stable regions —making them go-to names for institutional flows seeking a safe haven with yield.
<h3 class="wp-block-heading">Still More Upside If The Dollar Stays Soft</h3>
With the Federal Reserve leaning toward rate cuts and U.S. fiscal deficits ballooning, the dollar may have more downside ahead. 
That macro setup is gold-friendly, and <a href="https://www.goldmansachs.com/insights/articles/why-gold-prices-are-forecast-to-rise-to-new-record-highs">analysts</a> are already floating $3,700/oz price targets for bullion before year-end. If the trend holds, the FX boost to revenue could continue padding these miners&#8217; bottom lines well into 2026.
For investors looking beyond Big Tech, this might be the moment to rotate into gold—not just as a hedge but for actual upside. In a market obsessed with AI, the real alpha is buried under the weight of a falling dollar, for now.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/45969041/barricks-top-gold-mine-placed-under-state-control">Barrick&#8217;s Top Gold Mine Placed Under State Control</a></li>
</ul>
Image: Shutterstock

Long Ideas

Commodities

Forex

Markets

These 3 Gold Stocks Have Rocketed 50%, Thanks To A Floundering Dollar

Texas Capital Securities analyst Alex Rygiel initiates coverage on LGI Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) with a Hold rating and announces Price Target of $56.

LGIH

Texas Capital Securities Initiates Coverage On LGI Homes with Hold Rating, Announces Price Target of $56

Events

OKLO

Live On CNBC, Oklo CEO Jacob DeWitte Discusses Its Stocks Price Action, U.S. Defense Contract

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>), a global digital operator, announces today that Kyivstar, VEON's digital operator in Ukraine, has joined forces with Ukraine's Ministry of Digital Transformation to develop Ukraine's first national large language model ("LLM") trained on Ukrainian-language data. The cooperation memorandum builds on VEON's and Kyivstar's pledge to invest USD 1 billion to rebuild Ukraine's digital infrastructure over 2023-2027.
The parties plan to develop Ukrainian LLM using open-source architectures and trained exclusively on Ukrainian data sources. In addition to capturing the full range of Ukrainian dialects, terminology, history, and cultural context, the project is designed to ensure that sensitive national data is securely stored and processed within Ukraine, a critical requirement for sectors such as government, defense, healthcare, and financial services.
The LLM will also serve as the foundation for AI-powered products and services, including legal and regulatory analysis tools, as well as specialized AI applications across both public and private sectors including in fields like education, finance, and health. Trained on Ukrainian data, the model is expected to deliver more accurate, relevant, and actionable insights for Ukrainian users than general-purpose global models.
Kyivstar will develop the LLM in collaboration with Ukraine's Ministry of Digital Transformation and the WINWIN AI Centre of Excellence. The first version of the Ukrainian LLM is scheduled for release by December 2025.

VEON

VEON's Kyivstar Join Forces With Ukraine's Ministry Of Digital Transformation To Develop Ukraine's First National Large Language Model Trained On Ukrainian-Language Data

Texas Capital Securities analyst Alex Rygiel initiates coverage on Green Brick Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRBK#NYSE">GRBK</a>) with a Buy rating and announces Price Target of $71.

GRBK

Texas Capital Securities Initiates Coverage On Green Brick Partners with Buy Rating, Announces Price Target of $71

Texas Capital Securities analyst Alex Rygiel initiates coverage on Century Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCS#NYSE">CCS</a>) with a Buy rating and announces Price Target of $68.

Texas Capital Securities Initiates Coverage On Century Communities with Buy Rating, Announces Price Target of $68

After months of cautious positioning and defensive sector leadership, investor sentiment appears to be shifting decisively toward risk-on assets. Several growth-oriented and <a href="https://www.benzinga.com/etfs">thematic ETFs</a> notched fresh 52-week highs on Monday, reflecting renewed enthusiasm for innovation, technology, and discretionary spending plays.
At the forefront of this momentum are the flagship ETFs from ARK Invest. The ARK Fintech Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#BATS">ARKF</a>) surged past $45, while the ARK Next Generation Internet ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#BATS">ARKW</a>) crossed $135, both marking their highest levels in a year, according to Barchart. Cathie Wood's funds, known for their aggressive bets on disruptive technologies, have benefited from investor optimism around artificial intelligence, blockchain adoption, and a potential easing of macroeconomic headwinds.
Also Read: <a href="https://www.benzinga.com/news/25/06/45959562/new-tngy-etf-offers-flexible-income-focused-exposure-to-us-energy-market">New TNGY ETF Offers Flexible, Income-Focused Exposure To US Energy Market</a>
Joining the rally is the Alger AI Enablers &amp; Adopters ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALAI#NYSE">ALAI</a>), which climbed over 1.2% to a new high of $29.36. The fund provides exposure to companies positioned to benefit from the widespread adoption of artificial intelligence, a theme that has captured investor imagination since the generative AI boom took hold last year.
Meanwhile, the Roundhill Sports Betting &amp; iGaming ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BETZ#NYSE">BETZ</a>) also hit a new milestone, gaining 2.6% on the day. With names like DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) and Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) in its portfolio, BETZ represents a high-risk, high-reward corner of the market tied closely to consumer discretionary spending and regulatory developments.
Even broader allocation strategies are showing signs of risk appetite. The iShares Core Aggressive Allocation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOA#NYSE">AOA</a>), which holds a mix of U.S. and international equities tilted toward growth, rose 0.78% to a 52-week high, indicating that investors are not only chasing niche themes but also expressing broader confidence in equity markets.
<h2 class="wp-block-heading">A Broader Shift Underway?</h2>
Market analysts attribute the surge in growth-themed ETFs to a confluence of factors: resilient economic data, moderating inflation, expectations of Federal Reserve rate cuts later this year, and strong earnings performance from tech giants.
The rally in these ETFs reflects a growing consensus that the U.S. economy might achieve a soft landing. When macro fear subsides, investors naturally rotate back into higher-growth, more volatile assets.
ARKW and ARKF in particular have become proxies for investor sentiment around next-generation tech, including blockchain, digital wallets, and AI. Despite past criticism over their high volatility, the funds have rallied sharply in 2025, with ARKW up over 23% year to date.
BETZ's strength, meanwhile, suggests discretionary themes are gaining favor again, an encouraging sign for sectors that depend on consumer confidence and disposable income. While not without regulatory risk, the legalization trend in online sports betting across several U.S. states continues to support the fund&#8217;s growth story.
<h2 class="wp-block-heading">Is This Rally Sustainable?</h2>
It should be noted that valuation risks remain elevated, and any disappointment in earnings or macro data could quickly reverse the risk-on trend.
Still, for now, the market appears to be in full growth mode. The simultaneous rise of thematic funds like ALAI, speculative bets like BETZ, and broader growth-tilted portfolios like AOA suggest this isn't a narrow rally driven by a few mega caps but a more widespread return of risk appetite.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45958642/big-money-dumps-spy-but-history-says-dont-panic">Big Money Dumps SPY, But History Says Don&#8217;t Panic</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

The Alger ETF Trust Alger AI Enablers & Adopters ETF

ALAI

ARKF

ARKW

BETZ

DKNG

FLUT

Risk-On Revival: Growth-Themed ETFs Hit 52-Week Highs As Market Calms Down

SLRX

Salarius Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 55.2%

Texas Capital Securities analyst Alex Rygiel initiates coverage on Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) with a Buy rating and announces Price Target of $29.

LEGH

Texas Capital Securities Initiates Coverage On Legacy Housing with Buy Rating, Announces Price Target of $29

Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) has entered into a strategic partnership with Interpublic Group of Companies, Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) Acxiom business to <a href="https://www.benzinga.com/markets/tech/25/06/45944386/snowflake-acxiom-partner-to-power-secure-ai-marketing-for-brands">build and deliver an AI-powered marketing data infrastructure</a>.
Unique interactions through one-on-one conversations during Snowflake's annual conference provide an "on-the-ground view of trends that we expect to drive fundamentals for the software market over the next 12-18 months," according to JPMorgan.
The Snowflake Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5a/mark-murphy">Analyst Mark Murphy</a> reiterated an Overweight rating and price target of $225.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The analyst provided these quotable quotes from Snowflake Summit 2025:
<ul class="wp-block-list">
<li>One of the system integrator (SI) contacts said about CEO Sridhar Ramaswamy, "I call Sridhar's policy GAGA – General Availability, General Availability. They're rolling out new products always, I love it."</li>
<li>Another SI contact said that some of their customers were generating returns on their AI investments in two to six months. He added that while the technology "itself is amazing," its rapid adoption is being curbed by "things like data readiness, governance, and change management."</li>
<li>"I'm positive on the federal opportunity and see a lot of potential in 2025," one of the contacts stated.</li>
<li>Another SI contact said, "Once Snowflake starts to really get used… it grows like wildfire."</li>
</ul>
SNOW Price Action: Shares of Snowflake had risen by 0.35% to $209.73 at the time of publication on Tuesday.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/analyst-ratings/25/06/45946624/canaan-stock-a-deep-dive-into-analyst-perspectives-8-ratings">Want AI Exposure? These 3 ETFs Offer Different Angles</a></li>
</ul>
Image: Shutterstock

Analyst Color

Reiteration

SNOW

Snowflake AI Push Gains Traction, JPMorgan Analyst Sees 'Potential'

Long-term care isn't just something to think about in your 80s. As Suze Orman points out in <a href="https://www.suzeorman.com/blog/Suze-School-for-Long-Term-Care-Insurance">her blog</a>, planning ahead — especially in your 50s or 60s — could make the difference between financial stability and burning through your retirement savings if the unexpected happens.
Here's why Orman says long-term care insurance deserves your attention now.
<h2 class="wp-block-heading">The Real Cost of Care Is Higher Than You Think</h2>
Needing <a href="https://www.benzinga.com/personal-finance/management/25/05/45707341/its-a-huge-problem-experts-urge-gen-xers-and-millennials-to-plan-for-long-term-carehttps://www.benzinga.com/personal-finance/management/25/05/45707341/its-a-huge-problem-experts-urge-gen-xers-and-millennials-to-plan-for-long-term-care">long-term care</a> might not mean living in a nursing home. In fact, less than 15% of long-term care happens in those facilities, according to Orman's blog. Most people receive care at home or in assisted living, which still comes with a hefty price tag — often between $5,000 and $8,000 per month. And in more intensive situations, monthly care can reach $25,000.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2">grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
If care lasts several years — the average is 3.8 years for men and 4.7 years for women — those costs can easily add up to hundreds of thousands of dollars. Alzheimer's, strokes, and other chronic conditions can push that timeline even longer.
Medicare only helps in the first three months after a hospitalization. After that, you're on your own — unless you have long-term care insurance, or you qualify for Medicaid by spending down nearly all your assets.
<h2 class="wp-block-heading">How Long-Term Care Insurance Works</h2>
<a href="https://www.benzinga.com/personal-finance/management/25/06/45930717/what-if-something-happens-to-the-person-in-control-of-an-irrevocable-trust-suze-orman-weighs-in">Orman</a> explains that LTC insurance kicks in when you need help with at least two of six basic daily activities — such as bathing or eating — for 90 days or more, or if you have a serious cognitive impairment.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
There are two main types of policies she lists:
<ol class="wp-block-list">
<li>Traditional LTC Insurance: This works much like health insurance — you pay a premium, and if you never need care, the money helps cover others' claims. Premiums can increase over time, unless you purchase a plan with guaranteed pricing. These plans may offer inflation protection and can be more affordable if you buy early.</li>
<li>Hybrid or Linked-Benefit Policies: These combine life insurance or annuities with long-term care coverage. If you never need care, your family still receives a death benefit. Premiums are usually guaranteed and require a larger upfront payment — often $100,000 or more. Some allow for flexible payments over time.</li>
</ol>
Several <a href="https://www.benzinga.com/money/best-hybrid-life-insurance-long-term-care-policies">hybrid plans</a> even offer 100% cash benefits, so you can choose your own caregivers, including family members.
<h2 class="wp-block-heading">What If You Can't Qualify for Insurance?</h2>
If you have health issues that prevent you from qualifying for standard LTC insurance, there are still options. Orman shares that fixed index annuities with long-term care riders may offer increased payouts if you need care later — sometimes double your monthly income for up to five years. These options typically have easier health requirements.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
<h2 class="wp-block-heading">Don't Count on the Government to Step In</h2>
Orman warned that while many state governments are implementing programs to assist with LTC, don't assume that it will provide everything you need. She listed Washington State as an example. They launched a public LTC program in 2023, funded by a payroll tax. But the lifetime benefit caps out at just $36,500 — less than six months of care in many places. Other states like California, New York and Minnesota are exploring similar programs, but none are expected to offer full financial protection.
<h2 class="wp-block-heading">Protecting Your Future</h2>
Orman urges individuals — especially those nearing or in retirement — to explore their options now. She emphasizes that even a modest LTC policy can make a big difference, covering part of the cost and preserving more of your <a href="https://www.benzinga.com/personal-finance/management/25/06/45825806/is-your-retirement-nest-egg-above-average-heres-what-people-have-in-their-401k-and-ira-at-each-age">retirement nest egg</a>.
As care costs rise, having a plan in place may give you and your family peace of mind — and keep your financial future intact.
Read Next:
<ul class="wp-block-list">
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

$25,000 Monthly Care Costs? Suze Orman Shows How Long-Term Care Insurance Can Protect Your Savings

Texas Capital Securities analyst Alex Rygiel initiates coverage on Beazer Homes USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>) with a Buy rating and announces Price Target of $25.

Texas Capital Securities Initiates Coverage On Beazer Homes USA with Buy Rating, Announces Price Target of $25

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 5 years by 19.18% on an annualized basis producing an average annual return of 33.3%. Currently, Fair Isaac has a market capitalization of $43.89 billion. 
Buying $100 In FICO: If an investor had bought $100 of FICO stock 5 years ago, it would be worth $427.36 today based on a price of $1803.05 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750171512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FICO

Here's How Much You Would Have Made Owning Fair Isaac Stock In The Last 5 Years

Macro Economic Events

Politics

Global

Economics

Reuters Cites German Chancellor Merz Telling Broadcaster ARD "Expect Deal With U.S. In Tariff Dispute Before Summer's Over"

WIIM

Comstock Resources shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $34 price target.

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">myelodysplastic syndrome (HR-MDS)</a>.
MDS is a group of cancers in which the bone marrow doesn&#8217;t produce enough healthy blood cells.
The primary outcome measure is overall survival (OS). Key secondary outcome measures include a modified overall response (mOR) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45948002/abbvie-provides-update-on-verona-trial-for-newly-diagnosed-higher-risk-myelodysplastic-syndromes" rel="noreferrer noopener">and complete remission (CR)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45079377/abbvie-scores-fda-approval-for-its-blockbuster-drug-rinvoq-to-treat-type-of-arthritis" rel="noreferrer noopener">AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis</a>
The trial did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.
Results from the VERONA trial will be available in a future medical congress and/or publication.
The treating physician will inform any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials.&nbsp;
These data do not impact any currently approved indications for venetoclax.
In the first quarter, AbbVie reported Venclexta&#8217;s revenues were&nbsp;$665 million, <a target="_blank" href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" rel="noreferrer noopener">up 8.3% year over year (+12.3%)</a>.
Last week, the U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie&#8217;s Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45890526/fda-expands-abbvies-mavyret-label-to-include-pediatric-patients-with-hepatitis-c-infection" rel="noreferrer noopener">or with compensated cirrhosis.</a>
With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
HCV is a highly infectious blood-borne disease affecting the liver.
<h2 class="wp-block-heading">AbbVie Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at AbbVie, an investor could make an assessment about a stock&#8217;s long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For AbbVie, the 200-day moving average sits at $188.78, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is below the current price of $189.54. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ABBV stock is trading lower by 1.47% to $188.06 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45946402/incytes-experimental-therapy-shows-platelet-normalization-and-safety-in-rare-blood-cancer-trials-across-doses" target="_blank" rel="noreferrer noopener">Incyte&#8217;s Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Large Cap

ABBV

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and raises the price target from $8 to $9.

SAGE

Truist Securities Maintains Hold on Sage Therapeutics, Raises Price Target to $9

Press Releases

UPDATE: Sonim Technologies Announced as Latest "Verizon Frontline Verified" Partner

Sonim Technologies Reports Full Year 2024 Financial Results

Sonim Technologies, Inc. Special Committee Confirms Receipt of Unsolicited Proposal for $4.00 per Share in Cash

Sonim Technologies Announces Engagement with Shareholder Intelligence Services, LLC to Protect Shareholders and Maximize Value

Sonim Technologies Accelerates Expansion Strategy with Strong Momentum in the Second Quarter 2025

Sonim Announces Initial Purchase Orders For XP Pro Thermal Ahead of General Availability

Sonim Technologies Reports First Quarter 2025 Financial Results

Sonim Technologies Signs Letter of Intent to Sell Substantially All Assets to Social Mobile

Sonim XP Pro Lands at AT&T Friday, June 6

Sonim Technologies Confirms Receipt of Non-Binding Unsolicited Indication of Interest

Comments

Sonim Technologies

Intérêt court

Sonim Technologies (NASDAQ:SONM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL